Is TripAdvisor a Good Investment? This Hedge Fund Thinks So

TripAdvisor Inc (NASDAQ:TRIP) saw Luxor Capital Group increase its 2Q stake in the online travel company by over 100%, from 3 million shares at the end of June to 6.5 million shares, per a 13G filing at the end of September. Christian Leone founded Luxor Capital, a New York-based hedge fund, in 2002. Prior to purchase of the new shares, TripAdvisor already made up over 6% of Luxor’s 2Q 13F portfolio.

Christian Leone

TripAdvisor operates in a more niche market than some of its competitors. TripAdvisor is a site that focuses on reviews and helps facilitate travel booking, where key competitors, such as Expedia Inc (NASDAQ:EXPE), Orbitz Worldwide, Inc. (NYSE:OWW), Priceline.com Inc (NASDAQ:PCLN), and Kayak Software Corp (NASDAQ:KYAK) actually handle travel bookings. Orbitz has had a tough time so far this year, down 30% year to date and missing last quarter EPS by 20%. As well, the President of the Orbitz.com segment has made a number of insider sales around $2.80 over the past few months. Of the top online travel companies, Orbitz is definitely the most undersized at a market cap below $250 million. Orbitz, with its sub-$5 stock price and low market cap has attracted little fund interest; however, Par Capital, a fund with substantial interest in the travel industry owned 24.6 million shares.

Expedia is relatively flat since the TripAdvisor spin off. Expedia is still one of the largest online travel companies and includes other businesses, Hotels.com and Hotwire. The big worry for Expedia is its large exposure to Europe, in addition to the company’s European concerns over its lack of advertising without TripAdvisor. Expedia will likely see negative margin impacts from more advertising spending and technology innovation in 2012. As well as, they’ll probably see a less diverse revenue mix and more limited growth opportunities that puts this year’s EPS growth below 10%, versus the industry average of 24%.

Priceline is the behemoth of the industry, at a market cap of over $30 billion. The company expects to grow revenues by 19% in 2012 and 15% in 2013. However, much like Expedia, Priceline has significant exposure to Europe, where over half of Priceline’s gross bookings come from international business. Priceline’s exposure has only grown with recent acquisitions of Active Hotels and Bookings B.V., which are Internet hotel reservation service providers in Europe. Due to this European pressure, Priceline saw its price target lowered $50 to $700 by S&P; the company currently trades around $600 a share.

Kayak, the new comer to the travel industry with its summer-2012 IPO, is relatively flat since its NYSE debut. Although the company missed its first EPS estimate as a public company by 8%, the company is still expected to grow next year EPS by 35%. TSCHE Bank recently reiterated its buy rating on the company, with analyst Lloyd Walmsley citing that some of the weakness experienced by other online travel companies will be much different for Kayak given the company’s limited European exposure. In its most recent quarter, Kayak derived only 19% of revenues from Europe. However, our concern for Kayak’s current stock price is that the company trades at a high P/E ratio relative to the industry, at 50x trailing earnings.

Since TripAdvisor was spun off of Expedia in late 2011, the company is up 33%, but Luxor sees more upside, as do we—see our other thoughts on whether TripAdvisor is a good buy. We also believe that Expedia needed TripAdvisor more than TripAdvisor needed Expedia—see what hedge funds think of the travel industry. Other funds have also taken notice of TripAdvisor’s growth prospects. This includes Viking Global with 9 million shares and John Griffin with 5.6 million shares. Also, Philippe Laffont took an entirely new position in 2Q that was over 4 million shares. Although TripAdvisor trades above average on a P/E basis at 25, the company’s forward P/E is 18, as the company is expected to have a positive uptrend in EPS growth over the next five years, with an expected CAGR of 15%.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Most Awesome Hip Hop Documentaries

Foods That Stain Your Teeth

Richest Doctors in the World

The Best Movie Sountracks Ever

The Highest Grossing Musicals on Broadway

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!